Company: BDRX
Filing Date: 2025-04-29
Form Type: POS AM
Source: 0001214659-25-006581
Chunk: 3

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-04-29
Form: POS AM
Chunk 3
---
 Securities Purchase Agreement, dated as of January
17, 2025, by and between us and C/M, or the Purchase Agreement, establishing an equity line of credit, or the Equity Financing. Such Depositary
Shares include (a) 33,413,549 Depositary Shares, or the Purchase Shares, underlying 334,135,490,000 Ordinary Shares by that we may elect,
in our sole discretion, to issue and sell to the Selling Shareholder, from time to time from and after the Commencement Date (as defined
herein) under the Purchase Agreement, and subject to applicable stock exchange rules (assuming the shares to be issued and sold at a price
of $1.00 per share) and (b) up to 721,651 Depositary Shares, or the Commitment Shares, underlying 7,216,510,000 Ordinary Shares that may
be issued to the Selling Shareholder to release the Company of its liability to pay the Commitment Fee (as defined herein) as consideration
for it entering into the Purchase Agreement (assuming the shares to be issued at a price of $1.00 per share).

The actual number of shares
issuable will vary depending on the then-current market price of our Depositary Shares sold to the Selling Shareholder under the Purchase
Agreement, but will not exceed the number set forth in the preceding sentences unless we file an additional registration statement under
the Securities Act of 1933, as amended, or the Securities Act, with the Securities and Exchange Commission, or SEC. See “The Committed Equity Financing” for a description of the Purchase Agreement and “Selling Shareholder” for additional
information regarding the Selling Shareholder.

We are not selling any securities under this prospectus and will not receive any of the proceeds from the sale of the Depositary Shares by the Selling Shareholder. Additionally, we will not receive any proceeds from the issuance or sale of the Commitment Shares, if issued to release the Company of its liability to pay the Commitment Fee (as defined herein). However, we may receive up to $35.0 million in aggregate gross proceeds fromthe Selling Shareholder under the Purchase Agreement in connection with sales of Depositary Shares tothe Selling Shareholder pursuant to the Purchase Agreement after the date of this prospectus. The purchase price per Depositary Share thatthe Selling Shareholder
will pay for Depositary Shares purchased from us under the Purchase Agreement will fluctuate based on the market price of our Depositary Shares at the